Management Update

RNS Number : 3312H
Alliance Pharma PLC
23 November 2022
 

 

For immediate release

23 November 2022

 

Icon Description automatically generated with low confidence

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Management update

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that Peter Butterfield, Chief Executive Officer, is taking time away from the business for personal reasons. He is expected to return during January 2023.

 

Andrew Franklin, Chief Financial Officer, has assumed Peter's CEO responsibilities, in line with the Group's established resilience plans, with support from the Head of Finance and the wider leadership team.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website www.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGLBDBGSDDGDX
UK 100

Latest directors dealings